NCT05522868View on ClinicalTrials.gov

SB17170 Phase 1 Clinical Trial in Solid Tumors

PHASE1Active, not recruitingINTERVENTIONAL

Enrollment

50

Participants

Timeline

Start Date

October 17, 2022

Primary Completion Date

September 30, 2025

Study Completion Date

October 30, 2025

Conditions

Solid Tumor

Interventions

DRUG

SB17170

SB17170 capsules, Oral administration 21days/cycle

Trial Locations (3)

Unknown

Asan Medical Center, Seoul

Seoul National University Hospital, Seoul

Severance Hospital, Seoul

Sponsors

Lead Sponsor

SPARK Biopharma

All Listed Sponsors

lead

SPARK Biopharma

INDUSTRY